Shore Capital Partners platform company Argentum Medical has acquired the TheraBond family of products from Alliqua BioMedical (Alliqua).
These products, branded TheraBond with unique SilverTrak technology, include contact dressings, island dressings and wraps for burn care, surgical site care, and wound care.
“Alliqua has done an excellent job establishing these products as reliable, high-quality solutions for treating burns and other advanced wound care applications, and we have enjoyed working with them on this transaction,” says Raul Brizuela, President and CEO of Argentum. “We are excited to add the TheraBond products to Argentum’s existing market leading Silverlon silver plated nylon product portfolio, further strengthening our clinically proven and cost-effective offering for clinicians and patients in all advanced wound care settings.”
“This is an important acquisition for Argentum, and is consistent with the strategy we developed when we partnered with Raul Brizuela and the management team at Argentum earlier this year,” says Don Pierce, a Partner of Shore Capital Partners and Chairman of the Board of Argentum. “This acquisition is an excellent fit with the broader strategy of building a leading platform serving the advanced wound care market. This product family will extend Argentum’s burn care penetration and increase the depth of its product portfolio.”
The TheraBond product line is based on a proprietary and patented manufacturing process where silver is bonded to the entire surface of all fibers of the TheraBond dressing. When TheraBond products are placed on the wound, bioactive ionic silver is released in the dressing at a controlled rate, promoting an optimal wound healing environment by creating an antimicrobial barrier to more effectively protect the wound. With its one-piece construction and unique struts between the contact and outer layers, TheraBond also enables efficient transfer of fluid and exudate away from the wound and into an outer absorptive dressing, while providing rapid, sustained antimicrobial barrier protection.
“We are pleased to complete the sale of our Therabond product line to Argentum, which will allow Alliqua the opportunity to strengthen our balance sheet and align our effort on our core capability as a regenerative technology company,” says David Johnson, Chief Executive Officer of Alliqua. “We believe Argentum will be a great partner for TheraBond and will allow the products to continue to help patients around the world.”
